From Delayed to Instant: FDA Opens Real-Time Window on Drug Safety

With FDA’s continuous efforts to provide high standard healthcare system comes the next step of providing a fast adverse reporting system, this milestone reflects a pivotal advancement in strengthening agency’s safety monitoring infrastructure, being committed to having a transparent real time protection of public health.

As FDA Commissioner “Marty Makary” highlighted adverse event reporting should be fast & efficient without having to wait for months until information to be public.

FDA Adverse Event Reporting System (FAERS) serves as the FDA’s main database for monitoring adverse events, serious medication errors, and product quality concerns related to prescription drugs and biologics, drawing reports from healthcare professionals, consumers, and manufacturers.

This transition is part of the FDA’s wider data modernization strategy, aimed at streamlining adverse event reporting systems and increasing reporting frequency to detect potential safety signals more quickly.

By embracing real-time reporting, the FDA is reinforcing its commitment to innovation, transparency, and safeguarding public health with greater speed and precision.

Learn more: FDA Begins Real-Time Reporting of Adverse Event Data | FDA